Inhibitory effects of commonly used herbal extracts on UGT1A1 enzyme activity

Xenobiotica

Volumn 40, Issue 10, 2010, Pages 663-669

  Mohamed, Mohamed Eslam F ^a   Tseng, Tiffany ^a   Frye, Reginald F ^a  

^a UNIVERSITY OF FLORIDA HEALTH   (United States)

Author keywords

EGCG; estradiol glucuronidation; Green tea; inhibition; milk thistle; UGT1A1

Indexed keywords

CIMICIFUGA RACEMOSA EXTRACT; ECHINACEA EXTRACT; EPIGALLOCATECHIN GALLATE; GARLIC EXTRACT; GINSENG EXTRACT; GLUCURONOSYLTRANSFERASE 1A1; HERBACEOUS AGENT; SABAL EXTRACT; SILYBUM MARIANUM EXTRACT; VALERIAN;

ARTICLE; CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVITY; ENZYME INHIBITION; GLUCURONIDATION; HUMAN; HUMAN CELL; IC 50; LIVER MICROSOME;

CATECHIN; DRUG EVALUATION, PRECLINICAL; ECHINACEA; ESTRADIOL; GLUCURONOSYLTRANSFERASE; HUMANS; INHIBITORY CONCENTRATION 50; MICROSOMES, LIVER; MILK THISTLE; PLANT EXTRACTS;

ALLIUM SATIVUM; CIMICIFUGA DAHURICA; PANAX GINSENG; SERENOA REPENS; SILYBUM MARIANUM; VALERIANA;

EID: 77956575028     PISSN: 00498254     EISSN: 13665928     Source Type: Journal    
DOI: 10.3109/00498254.2010.505669     Document Type: Article

References (35)

1. Alkharfy KM, Frye RF. (2002). Sensitive liquid chromatographic method using fuorescence detection for the determination of estradiol 3-and 17-glucuronides in rat and human liver micro-somal incubations: formation kinetics. J Chromatogr B Analyt Technol Biomed Life Sci 774:33-38.
2. Barnes PM, Bloom B, Nahin RL. (2008). Complementary and alternative medicine use among adults and children: United States, 2007. Natl Health Stat Report 1-23.
3. Butterweck V, Derendorf H. (2008). Potential of pharmacokinetic profling for detecting herbal interactions with drugs. Clin Pharmacokinet 47:383-397.
4. Copeland, RA. (2005). Evaluation of enzyme inhibitors in drug discovery: a guide for medicinal chemists and pharmacologists. Hoboken, N.J.: Wiley-Interscience.
5. Court MH. (2005). Isoform-selective probe substrates for in vitro studies of human UDP-glucuronosyltransferases. Meth Enzymol 400:104-116.
6. Cummings SR, Eckert S, Krueger KA, Grady D, Powles TJ, Cauley JA, Norton L, Nickelsen T, Bjarnason NH, Morrow M, Lippman ME, Black D, Glusman JE, Costa A, Jordan VC. (1999). Te efect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. JAMA 281:2189-2197.
7. D'Andrea V, Pérez LM, Sánchez Pozzi EJ. (2005). Inhibition of rat liver UDP-glucuronosyltransferase by silymarin and the metabolite silibinin-glucuronide. Life Sci 77:683-692.
8. Doerge DR, Chang HC, Churchwell MI, Holder CL. (2000). Analysis of soy isofavone conjugation in vitro and in human blood using liquid chromatography-mass spectrometry. Drug Metab Dispos 28:298-307.
9. Eisenberg DM, Davis RB, Ettner SL, Appel S, Wilkey S, Van Rompay M, Kessler RC. (1998). Trends in alternative medicine use in the United States, 1990-1997: results of a follow-up national survey. JAMA 280:1569-1575.
10. FDA. (2006). Draft guidance for industry: drug interaction studies-study design, data analysis, and implications for dosing and labeling. Available at:. Accessed on 26 March 2010.
11. Fisher MB, Labissiere G. (2007). Te role of the intestine in drug metabolism and pharmacokinetics: an industry perspective. Curr Drug Metab 8:694-699.
12. Foster DR, Sowinski KM, Chow HH, Overholser BR. (2007). Limited sampling strategies to estimate exposure to the green tea polyphe-nol, epigallocatechin gallate, in fasting and fed conditions. Ter Drug Monit 29:835-842.
13. Gardiner P, Phillips R, Shaughnessy A F. (2008). Herbal and dietary supplement-drug interactions in patients with chronic illnesses. Am Fam Physician 77:73-78.
14. Ghosal A, Hapangama N, Yuan Y, Achanfuo-Yeboah J, Iannucci R, Chowdhury S, Alton K, Patrick JE, Zbaida S. (2004). Identifcation of human UDP-glucuronosyltransferase enzyme(s) responsible for the glucuronidation of ezetimibe (Zetia). Drug Metab Dispos 32:314-320.
15. Guillemette C, Lévesque E, Harvey M, Bellemare J, Menard V. (2010). UGT genomic diversity: beyond gene duplication. Drug Metab Rev 42:22-42.
16. Hellum BH, Hu Z, Nilsen OG. (2007). Te induction of CYP1A2, CYP2D6 and CYP3A4 by six trade herbal products in cultured primary human hepatocytes. Basic Clin Pharmacol Toxicol 100:23-30.
17. Izzo AA, Ernst E. (2009). Interactions between herbal medicines and prescribed drugs: an updated systematic review. Drugs 69:1777-1798.
18. Kemp DC, Fan PW, Stevens JC. (2002). Characterization of raloxifene glucuronidation in vitro: contribution of intestinal metabolism to presystemic clearance. Drug Metab Dispos 30:694-700.
19. Lépine J, Bernard O, Plante M, Têtu B, Pelletier G, Labrie F, Bélanger A, Guillemette C. (2004). Specifcity and regioselectivity of the conjugation of estradiol, estrone, and their catecholestrogen and methoxyestrogen metabolites by human uridine diphospho-glucuronosyltransferases expressed in endometrium. J Clin Endocrinol Metab 89:5222-5232.
20. Lu H, Meng X, Li C, Sang S, Patten C, Sheng S, Hong J, Bai N, Winnik B, Ho CT, Yang CS. (2003). Glucuronides of tea catechins: enzymol-ogy of biosynthesis and biological activities. Drug Metab Dispos 31:452-461.
21. Mano Y, Usui T, Kamimura H. (2005). In vitro inhibitory efects of non-steroidal antiinfammatory drugs on UDP-glucuronosyltransferase 1A1-catalysed estradiol 3beta-glucuronidation in human liver microsomes. Biopharm Drug Dispos 26:35-39.
22. Medical Economics Company (1998). PDR for herbal medicines. Montvale, N.J.: Medical Economics Co.
23. Moore RJ, Jackson KG, Minihane AM. (2009). Green tea (Camellia sinensis) catechins and vascular function. Br J Nutr 102:1790-1802.
24. Nagle DG, Ferreira D, Zhou YD. (2006). Epigallocatechin-3-gallate (EGCG): chemical and biomedical perspectives. Phytochemistry 67:1849-1855.
25. NBJ (2007). NBJ's Supplement Business Report. Nutr Bus J.
26. Ouzzine M, Barré L, Netter P, Magdalou J, Fournel-Gigleux S. (2003). Te human UDP-glucuronosyltransferases: structural aspects and drug glucuronidation. Drug Metab Rev 35:287-303.
27. Schrieber SJ, Wen Z, Vourvahis M, Smith PC, Fried MW, Kashuba AD, Hawke RL. (2008). Te pharmacokinetics of silymarin is altered in patients with hepatitis C virus and nonalcoholic Fatty liver disease and correlates with plasma caspase-3/7 activity. Drug Metab Dispos 36:1909-1916.
28. Schulz C, Boeck S, Heinemann V, Stemmler HJ. (2009). UGT1A1 geno-typing: a predictor of irinotecan-associated side efects and drug efcacy? Anticancer Drugs 20:867-879.
29. Sloley BD, Lin YC, Ridgway D, Semple HA, Tam YK, Coutts RT, Lobenberg R, Tam-Zaman N. (2006). A method for the analysis of ginsenosides, malonyl ginsenosides, and hydrolyzed ginse-nosides using high-performance liquid chromatography with ultraviolet and positive mode electrospray ionization mass spec-trometric detection. J AOAC Int 89:16-21.
30. Strandell J, Neil A, Carlin G. (2004). An approach to the in vitro evaluation of potential for cytochrome P450 enzyme inhibition from herbals and other natural remedies. Phytomedicine 11:98-104.
31. van Erp NP, Baker SD, Zhao M, Rudek MA, Guchelaar HJ, Nortier JW, Sparreboom A, Gelderblom H. (2005). Efect of milk thistle (Silybum marianum) on the pharmacokinetics of irinotecan. Clin Cancer Res 11:7800-7806.
32. Williams JA, Hyland R, Jones BC, Smith DA, Hurst S, Goosen TC, Peterkin V, Koup JR, Ball SE. (2004). Drug-drug interactions for UDP- glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCi/AUC) ratios. Drug Metab Dispos 32:1201-1208.
33. Williams JA, Ring BJ, Cantrell VE, Campanale K, Jones DR, Hall SD, Wrighton SA. (2002). Diferential modulation of UDP-glucuronosyltransferase 1A1 (UGT1A1)-catalyzed estradiol-3-glucuronidation by the addition of UGT1A1 substrates and other compounds to human liver microsomes. Drug Metab Dispos 30:1266-1273.
34. Zhang L, Zuo Z, Lin G. (2007). Intestinal and hepatic glucuronidation of favonoids. Mol Pharm 4:833-845.
35. Zhu BT, Taneja N, Loder DP, Balentine DA, Conney AH. (1998). Efects of tea polyphenols and favonoids on liver microsomal glucuro-nidation of estradiol and estrone. J Steroid Biochem Mol Biol 64:207-215.